Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 10, 2025 07:00 ET
|
Immunocore Holdings plc
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 08:00 ET
|
Liquidia Corporation
Liquidia's Chief Executive Officer, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:05 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 07:00 ET
|
Immunocore Holdings plc
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
December 18, 2024 07:55 ET
|
ZyVersa Therapeutics
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024 15:13 ET
|
Tevogen Bio Inc
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
HEI Civil Announces Appointment of JP Morgan to Chief Operating Officer
November 12, 2024 12:00 ET
|
HEI Civil
CASTLE ROCK, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- HEI Civil, a national heavy civil construction company, is pleased to announce the promotion of JP Morgan to Chief Operating Officer. Morgan...
Recursion to Participate in Upcoming Investor Conferences
June 03, 2024 09:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024 08:01 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...